Abstract:Runqian Huang, 1, &ast Chunling Zheng, 1, 2, &ast Guixiao Xu, 1 Xuanwei Chen, 1 Jingxian Shen, 1 Siyue Mao 1 1 Department of Radiology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China; 2 Department of Radiology, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong Province, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jingxian Shen; Siyue Mao, Department of Radiology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Sun Yat-sen University, 651 Dongfeng Road East, Guangzhou, 510060, People's Republic of China, Tel/Fax +86-20-87343217, Email ; Objective: To identify imaging features that help distinguish between HCCs and non-HCC malignancies assigned to LI-RADS M (LR-M) and evaluate the diagnostic performance of a LI-RADS with targetoid criteria using thin-rim arterial phase hyperenhancement (APHE). Materials and Methods: This retrospective study included 381 patients (387 observations) at high-risk for HCC who underwent enhanced-MRI before surgery. Three radiologists reviewed images for LI-RADS categorization of hepatic observations. Univariate and multivariate analysis was conducted to determine reliable features to differentiate between HCC and non-HCC malignancies among the LR-M lesions. The thin-rim (< 30%) APHE was defined based on the thickest thickness of rim APHE compared with the tumor radius, and a modified LI-RADS emphasizing thin-rim APHE as a specific feature of LR-M was established. We compared the diagnostic performance of modified LR-M and LI-RADS 5 (LR-5) with the conventional one. Results: Thin-rim APHE and targetoid diffusion-weighted imaging (DWI) were found as independent predictive factors of non-HCC malignancies, while enhancing capsule, thick-rim APHE and peripheral washout were noted as independent variables significantly associated with HCC of LR-M ( P < 0.05). The noticeable diagnostic performance of thin-rim APHE in distinguishing non-HCC malignancies from HCCs using the ROC curve. Emphasizing thin-rim APHE on targetoid features, the modified LR-M revealed significantly superior specificity and accuracy (89.4% vs 81.1%, P =0.004; and 87.9% vs 82.2%, P =0.027, respectively) while maintaining high sensitivity (82.2% vs 86.0%; P =0.529) compared with the LR-M. Meanwhile, the modified LR-5 achieved greater sensitivity and accuracy (88.6% vs 79.7%, P =0.004; and 85.8% vs 80.1%, P =0.036, respectively) for diagnosing HCC, without compromising specificity (78.3% vs.81.1%; P =0.608) compared with the LR-5. Conclusion: Thin-rim APHE may be the specific imaging feature for differentiating non-HCC malignancies from HCCs within LR-M. The modified targetoid criteria emphasizing thin-rim APHE can improve the diagnostic performance of LI-RADS for hepatic malignancies. Keywords: hepatic tumors, malignant, targetoid feature, Rim APHE, liver imaging reporting and data system The Liver Imaging Reporting and Data System version 2018 (LI-RADS v2018) aims to standardize the interpretation and reporting of hepatic lesions in patients who are at a high-risk of hepatocellular carcinoma (HCC). 1–3 In these patients, the distinction between HCCs and non-HCC malignancies is important for improving therapeutic and prognostic methods. 4–7 Therefore, the LI-RADS v2018 provides a LI-RADS M (LR-M) category for hepatic observations that may reflect malignancy, while it is unspecific to HCC. 1 Hepatic observations showing any targetoid features, such as rim arterial-phase hyperenhancement (APHE), peripheral washout, delayed central enhancement and targetoid appearance on diffusion-weighted imaging (DWI) or transitional phase/hepatobiliary phase (TP/HBP), can be categorized into LR-M category. 1 A meta-analysis 8 that involved 1819 LR-M lesions from 10 studies demonstrated that among the LR-M imaging features, rim APHE showed the highest pooled frequency in both non-HCC malignancies (48.9%) and HCCs (9.8%). Besides, as reported by Kim et al, 9 rim APHE was the most sensitive feature of LR-M, and it was highly valuable for classifying non-HCC malignancies in patients with liver cirrhosis. Though the LR-M imaging features was commonly used to characterize non-HCC malignancies, which mostly presented as intrahepatic cholangiocarcinoma (ICC) and combined hepatocellular-cholangiocar -Abstract Truncated-

A Modified Targetoid Feature Emphasizing Thin-Rim APHE to Improve the Diagnostic Performance of LI-RADS for Malignant Hepatic Tumors

DIAGNOSTIC PERFORMANCE OF CLASSICAL/MODIFIED CEUS LI-RADS WITH PERFLUOROBUTANE CONTRAST AGENT IN HIGH-RISK HEPATOCELLULAR CARCINOMA

Based on Gadolinium Ethoxybenzyl DTPA–Enhanced MRI: Diagnostic Performance of the Category-Modified LR-5 Criteria in Patients At Risk for Hepatocellular Carcinoma

A convenient scoring system to distinguish intrahepatic mass-forming cholangiocarcinoma from solitary colorectal liver metastasis based on magnetic resonance imaging features

MRI-Based Radiomics Models to Discriminate Hepatocellular Carcinoma and Non-Hepatocellular Carcinoma in LR-M According to LI-RADS Version 2018

Diagnostic Performance of LI-RADS Version 2018 for Primary Liver Cancer in Patients With Liver Cirrhosis on Enhanced MRI

LI-RADS M (LR-M) criteria and reporting algorithm of v2018: diagnostic values in the assessment of primary liver cancers on gadoxetic acid-enhanced MRI

Diagnostic value of liver imaging reporting and data system on hepatocellular carcinoma

Liver imaging reporting and data system category M: A systematic review and meta‐analysis

Clinical Application of Liver Imaging Reporting and Data System for Characterizing Liver Neoplasms: A Meta-Analysis

Simplified liver imaging reporting and data system for the diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging

LI-RADS for MR Imaging Diagnosis of Hepatocellular Carcinoma: Performance of Major and Ancillary Features

Prediction of Microvascular Invasion and Recurrence After Curative Resection of LI-RADS Category 5 Hepatocellular Carcinoma on Gd-BOPTA Enhanced MRI

LI-RADS for CT diagnosis of hepatocellular carcinoma: performance of major and ancillary features

Individual Participant Data Meta-Analysis of LR-5 in LI-RADS Version 2018 versus Revised LI-RADS for Hepatocellular Carcinoma Diagnosis

Efficacy of Multiple Modified Methods of Criteria for LR-M Liver Nodules of Different Sizes Clinical Practice and Discussion in CEUS LI-RADS Version 2017

Efficacy of Multiple Modified Methods of Criteria for LR‐M Liver Nodules of Different Sizes

Liver Imaging Reporting and Data System:: Substantial Discordance Between CT and MR for Imaging Classification of Hepatic Nodules.

Hepatocellular carcinoma (HCC) versus non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018

The Role of Enhancing Capsule and Modified Capsule Appearances in LI-RADS for Diagnosing HCC ≤ 3.0 Cm on Gadoxetate Disodium–enhanced MRI

Expanding the Liver Imaging Reporting and Data System (LI-RADS) v2018 diagnostic population: performance and reliability of LI-RADS for distinguishing hepatocellular carcinoma (HCC) from non-HCC primary liver carcinoma in patients who do not meet strict LI-RADS high-risk criteria